$heff's $tation of $tocks & $olid DD

[Investor100]

Highlights @ POZN

PPS:$11.00

Some highlights @ POZN

1) Company with solid data and p values that are statistically significant in all the endpoints.

2) Company that has Special Protocol Assessments with the FDA on 2 drugs (including Vimovo).

3) Company has always been debt free in 10 years of being a public company.

4) Company has never diluted their shares or gone to the market for financing.

5) The market needs an agent for pain without the GI toxicity. Clinical data shows this company has a plan in place to address this need.

6) Astra Zeneca and Glaxo Smithkline are already partnered with PONZ.

7) The royalty opportunities for POZN are strong:POZN will get $20 million if Vimovo is approved, along with royalty payments on sales.

GLTA

Investor 100